Nafarelin for endometriosis

NANCY C. SHARTS-ENGEL, N C Sharts-Engel, Sharts-Engel NC
MCN. The American journal of maternal child nursing · 1992 · vol. 17(4) , pp. 224 · doi:10.1097/00005721-199207000-00022 · PMID:1386133 · W2088115974
Other OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-17 ⓘ

This paper reviews the use of nafarelin, a gonadotropin-releasing hormone agonist, as a treatment option for endometriosis, discussing its efficacy and side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

MCN, The American Journal of Maternal/Child Nursing: July 1992 - Volume 17 - Issue 4 - p 224

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Danazol Danazol Danazol Endometriosis Endometriosis Female Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Humans Nafarelin Nafarelin

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

europepmc
last seen: 2026-10-22T06:08:12.857683+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:01:48.093215+00:00
License: CC0 · commercial use OK